Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Assets Average (2016 - 2025)

Historic Assets Average for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $812.7 million.

  • Corcept Therapeutics' Assets Average rose 844.12% to $812.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $812.7 million, marking a year-over-year increase of 844.12%. This contributed to the annual value of $731.0 million for FY2024, which is 2133.89% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Assets Average of $812.7 million as of Q3 2025, which was up 844.12% from $824.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Assets Average ranged from a high of $843.5 million in Q1 2025 and a low of $445.9 million during Q1 2022
  • Over the past 5 years, Corcept Therapeutics' median Assets Average value was $576.9 million (recorded in 2021), while the average stood at $626.9 million.
  • Its Assets Average has fluctuated over the past 5 years, first tumbled by 2066.04% in 2022, then skyrocketed by 3469.07% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Assets Average stood at $504.6 million in 2021, then rose by 10.66% to $558.3 million in 2022, then rose by 8.85% to $607.8 million in 2023, then surged by 33.67% to $812.4 million in 2024, then increased by 0.03% to $812.7 million in 2025.
  • Its Assets Average was $812.7 million in Q3 2025, compared to $824.1 million in Q2 2025 and $843.5 million in Q1 2025.